discharged home from the procedure. At 1 year post-MitraClip, CRT non-responders showed improvements from baseline in clinical and functional measures (Table) including a 27% reduction in rate of HF hospitalizations.
Background: Percutaneous mitral valve repair using the transcatheter MitraClip device is a novel therapy recently FDA approved for patients with severe degenerative mitral regurgitation (DMR) who are at prohibitive risk for surgery. We herein report the results of an ongoing single-center post-market series in the United States. Methods: Patients were screened with transthoracic (TTE) and transesophageal echocardiography (TEE). Between November of 2013 and April of 2014, 97 patients presented with severe (4+) DMR. Mitral valve surgery was performed in 76 (78.4%) of these patients. A multi-disciplinary heart team deemed 21 (21.6%) patients to be at prohibitive risk for surgery. The MitraClip was deployed under 2-and 3-dimensional TEE, 3D real-time intracardiac echocardiography, and fluoroscopic guidance. Results: Mean age was 78AE9 years and the average STS score was 12.2%. MitraClip deployment was successful in 20/21 patients (95.3%); 1 case was unsuccessful due to a very small left atrium. Two clips were deployed in 3 patients (14.3%). There were no vascular complications, strokes or procedural deaths. At 30 days there were 2 patients had died (9.5%), 1 due to respiratory failure at 48 hours and 1 due to a stroke at 3 weeks. At 1-month follow-up, 17 patients (81.0%) had Grade 1-2+ MR. Left ventricular ejection fraction was unchanged from baseline to 1 month (mean 40% to 39.5% respectively, P¼0.80). NYHA class, however, improved significantly following intervention with 72.7% of patients being NYHA class I/II at 1 month compared to 12.5% at baseline (P¼0.0002). Mean BNP levels decreased significantly following MitraClip from 1739 pg/ml at baseline to 377.84 pg/ml at 1 month (P¼0.02). Conclusions: In our experience approximately 1 in 5 patients with severe DMR may not be eligible for mitral valve surgery. MitraClip edge-to-edge repair is feasible in such patients, and successfully reduces the severity of MR while improving NYHA class in the majority. Further studies are needed to examine whether these results are durable and associated with improved outcomes.
TCT-790

Impact of Percutaneous Mitral Valve Repair on Tricuspid Regurgitation
Antonio H. Frangieh 1 , Christiane Gruner 1 , Fran Mikulicic 1 , Felix Tanner 1 , Roberto Corti 2 , Jürg Grünenfelder 2 , Dominique Bettex 1 , Oliver Gaemperli 1 1 University Hospital of Zurich, Zurich, Switzerland, 2 Klinik Hirslanden, Zurich, Switzerland Background: Tricuspid regurgitation (TR) and right ventricular (RV) dysfunction have been identified as significant predictors of outcome after mitral valve surgery. Notably, mitral valve surgery tends to worsen TR and RV parameters. However, the impact of percutaneous mitral valve repair (PMVR) with the MitraClip system in TR and RV parameters has not been investigated yet. Methods: We retrospectively assessed TR and RV function parameters on baseline and follow-up (3-12 months after PMVR) transthoracic echocardiography of 60 consecutive patients (mean age 72AE11 years, male gender 65.6%) with functional (57.4%), degenerative (32.8%), or mixed (9.8%) mitral regurgitation (MR), who underwent PMVR using the MitraClip system. TR was graded on a scale from 1 to 3 according to recommendations of the American Society of Echocardiography. RV function was analyzed using the fractional area change (FAC) and tricuspid anular plane systolic excursion (TAPSE). Results: Acute procedural success of PVMR was achieved in 56 (93%) patients. Baseline TR was grade 1 in 23 (38%), grade 2 in 18 (30%), and grade 3 in 19 (32%) patients. TR change (by at least one grade) after PMVR was as follows: decrease in 20 (33%) and increase in 7 (12%) patients (p¼0.039). Systolic RV function (pre/post FAC and TAPSE) did not change significantly. The tricuspid annular diameter also remained unchanged. There was a trend toward a decrease in maximum pressure gradient across the tricuspid valve (36 mmHg versus 33 mmHg, p¼0.14) which was poorly correlated with improvement in TR severity (OR 1.07; p¼0.018). These findings were accompanied by a significant improvement of NYHA functional class (p< 0.01). Conclusions: In patients with severe MR, PMVR using the MitraClip device improves TR. Reduction of TR is associated with the improvement of symptomatic status after PMVR. A transcatheter TR solution is required for those patients who experience worsening of TR despite improvement of MR.
TCT-791
The MitraClip Procedure For Functional Mitral Regurgitation: Improved Outcomes For Both Ischemic and Non-Ischemic Types
Wen Loong Yeow 1 , Takashi Matsumoto 1 , Harrison Dinh 1 , Alfredo Trento 1 , Asma Hussaini 1 , Moody Makar 1 , Robert Siegel 1 , Saibal Kar 1 1 Cedars-Sinai Medical Center, Los Angeles, CA Background: Outcomes of transcatheter mitral valve repair with the MitraClip in patients with ischemic or non-ischemic functional mitral regurgitation (FMR) have not been analyzed separately. Representing the largest single center experience of the MitraClip procedure in the US, we sought to determine if the outcomes differ between the two types. Methods: One hundred and eleven consecutive patients treated with the MitraClip procedure were analyzed and their outcomes were compared according to the type of FMR. Results: Baseline characteristic between the two types were similar except a preponderance of males and a higher STS score in the ischemic FMR group (Table 1) . Post-procedural reduction of FMR to grade 2+ or less was similar (60 (92%) ischemic vs 42 (91%) non-ischemic FMR, p¼0.56). Over a median follow-up of 23 months (IQR 11 to 40months), Kaplan-Meier estimates freedom from all cause death (37% vs 42% at 60-months, p¼0.77), heart failure hospitalization (77% vs 79% at 60-months, p¼0.44), cardiac surgery (84% vs 95% at 60-months, p¼0.39) and FMR grade 3+ or greater (79% vs 78% at 60-months, p¼0.99) were similar between ischemic and nonischemic FMR respectively.
Conclusions:
In this first-of-a-kind study from the largest single center experience of the MitraClip procedure in the US for ischemic and non-ischemic FMR, significant and sustained improvements in outcomes were similar for both types. Consequently, suitable patients with either subtype can be treated effectively. 
